On June 10, Novo Nordisk rose 3.13% in regular trading, trading at $42.29/share, with trading volume of $463 million. Multiple positive catalysts converged to drive the stock higher.
On the news front, several tailwinds provided support. Novo Nordisk disclosed that prescriptions for its oral version of Wegovy have surpassed 3 million since its January launch, with commercial ramp-up exceeding market expectations. Additionally, the oral formulation has officially launched in the UAE, marking the first market outside the United States and signaling continued international expansion.
The ongoing American Diabetes Association (ADA) Scientific Sessions also contributed to sentiment, with multiple clinical data readouts reinforcing the company's pipeline strength. Meanwhile, Novo Nordisk issued a statement addressing head-to-head study data presented at the conference, cautioning against premature interpretation of single-study results and emphasizing the need for comprehensive, multi-dimensional evidence assessment.
Within the Pharmacy sector, the overall tone was mixed. Among individual stocks, Eli Lilly up 0.09%, Johnson & Johnson up 2.21%, Merck up 0.55%, Pfizer up 0.53%, Bristol-Myers Squibb up 1.38%.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments